Draft of EU export restriction for COVID-19 vaccines
Government Funded research
Novavax and Inovio COVID-19 Vaccine Contracts Limit Prices Companies Can Charge for Their Products
One of the main objections to march-in rights and reasonable pricing clauses is the repeated assertion by NIH leadership that pharmaceutical companies would never agree to a partnership with the federal government that involves price constraints. This argument defies logic… Continue Reading
Agenda: Jan 27, 2021 Discussion of proposals to change Bayh-Dole regulations and Stevenson-Wydler Act statutes
This is the agenda for a discussion of proposals to change Bayh-Dole regulations and Stevenson-Wydler Act statutes. The proposals for the changes in regulations were noticed on January 4, 2021, and the proposed changes in the statutes were published on… Continue Reading
President Ursula von der Leyen on COVID-19 (Davos Agenda Week): “And now, the companies must deliver. They must honour their obligations.”
On Tuesday, 26 January 2021, Dr. Ursula von der Leyen, President of the European Commission delivered a special address at “Davos Agenda Week” devoting much of her speech to the European Union’s response to the COVID-19 pandemic. While President von… Continue Reading
WHO EB 148: KEI’s statement on expanding access to effective treatments for cancer and rare and orphan diseases including cell and gene-based therapies
At the meeting of the World Health Organization’s 148th Executive Board, Knowledge Ecology International delivered the following remarks on expanding access to effective treatments for cancer and rare and orphan diseases including cell and gene-based therapies on Friday, 22 January… Continue Reading
The European Commission-Curevac Advance Purchase Contract for a COVID-19 Vaccine
The European Commission has released a redacted version of a contract with Curevac for a COVID-19 vaccine. The vaccine uses mRNA technology, similar to the Pfizer and Moderna vaccines. The contract is severely redacted in some areas, but some information… Continue Reading
EB 148: WHO’s COVID-19 Technology Access Pool (C-TAP) comes under scrutiny
On Tuesday, 19 January 2021, the World Health Organization’s (WHO) Executive Board discussed the COVID-19 response. In these discussions, Knowledge Ecology International (KEI), and Health Action International (HAI) expressed concerns over WHO’s leadership of the COVID-19 Technology Access Pool (C-TAP).… Continue Reading
Online discussion of NIST proposals to change Bayh-Dole regulations and Stevenson-Wydler Act statutes – January 27, 2021 at 2PM
KEI will host an online discussion of the new end of Trump term proposals to change Bayh-Dole regulations and Stevenson-Wydler Act statutes, on January 27, 2021, from 2pm to 4pm. To register for the event, send an email to bayh-dole-proposals@keionline.org… Continue Reading
KEI Comments to NIH on Exclusive and Co-Exclusive Licenses to Senti Bio
Knowledge Ecology International (KEI) submitted comments to the National Institutes of Health (NIH) on January 12, 2021 regarding the “Prospective Grant of an Exclusive Patent License: Development and Commercialization of Chimeric Antigen Receptor (CAR) Therapies for the Treatment of FMS-Like… Continue Reading
KEI Comments on NIH Exclusive License to Morphiex for Cancer Treatment
(Update: The NIH provided a response to our comments on January 19, 2021) On January 12, 2021, Knowledge Ecology International (KEI) submitted comments to the National Institutes of Health (NIH) regarding the “Prospective Grant of an Exclusive Patent License: Use… Continue Reading